Clinical Trial Detail

NCT ID NCT03631784
Title A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799). (KEYNOTE-799)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Carboplatin + Paclitaxel + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.